The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs.
The effects of experimental design on the apparent solubility of two sparingly soluble hydrophilic compounds (barium sulphate and calcium carbonate) were studied in this paper. The apparent solubility appeared to be primarily dependent on the amount of solute added to the solvent in each experiment, increasing with increased amounts. This effect seems to be due to the existence of a peripheral disordered layer. However physico-chemical methods used in the present study were not able to unambiguously verify the existence of any disorder in the solid state structure of the drugs. At higher proportions of solute to solvent, the solubility reached a plateau corresponding to the solubility of the disordered or amorphous molecular form of the material. Milling the powders caused the plateau to be reached at lower proportions of solute to solvent, since this further disordered the surface of the drug particles. It was also found that the apparent solubility of the drugs tested decreased after storage at high relative humidities. A model for describing the effects of a disordered surface layer of varying thickness and continuity on the solubility of a substance is presented. This model may be used as a method for detection of minute amount of disorder, where no other technique is capable of detecting the disordered structure. It is suggested that recrystallisation of the material occurs via slow solid-state transition at the surface of the drug particle; this would slowly reduce the apparent solubility of the substance at the plateau level to the thermodynamically stable value. A biphasic dissolution rate profile was obtained. The solubility of the disordered surface of the particles appeared to be the rate-determining factor during the initial dissolution phase, while the solubility of the crystalline core was the rate-determining factor during the final slower phase.
Mosharraf
M
M
Uppsala University, Department of Pharmacy, Sweden.
Sebhatu
T
T
Nyström
C
C
D001464:Barium / Q000032:analysis; D001466:Barium Sulfate / Q000737:chemistry*; D002118:Calcium / Q000032:analysis; D002119:Calcium Carbonate / Q000737:chemistry*; D003124:Colorimetry; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D006813:Humidity; D010316:Particle Size; D010968:Plasticizers; D011208:Powders / Q000737:chemistry*; D012995:Solubility; D014961:X-Ray Diffraction
D010968:Plasticizers; D011208:Powders; D001464:Barium; D001466:Barium Sulfate; D002119:Calcium Carbonate; D002118:Calcium